BeiGene Announces National Reimbursement Inclusion of VIDAZA by the State Medical Insurance Administration in China
pharmaceutical investing BeiGene Announces Acceptance of New Drug Application for Anti-PD-1 Antibody Tislelizumab in Hodgkin’s Lymphoma in China
Steadright Files Q1 Interim FS and MD&A / Moroccan Site and Cancellation of Crushing & Grinding Equipment Share Purchase Agreement With Possible Renegotiation
